Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $401.3 million.

  • Karyopharm Therapeutics' Total Liabilities rose 1452.68% to $401.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $401.3 million, marking a year-over-year increase of 1452.68%. This contributed to the annual value of $401.3 million for FY2025, which is 1452.68% up from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Total Liabilities of $401.3 million as of Q4 2025, which was up 1452.68% from $365.5 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Total Liabilities ranged from a high of $401.3 million in Q4 2025 and a low of $314.5 million during Q1 2021
  • Moreover, its 5-year median value for Total Liabilities was $370.7 million (2023), whereas its average is $364.8 million.
  • Per our database at Business Quant, Karyopharm Therapeutics' Total Liabilities soared by 4974.21% in 2021 and then tumbled by 1066.33% in 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Total Liabilities (Quarter) stood at $385.0 million in 2021, then decreased by 2.64% to $374.8 million in 2022, then grew by 0.48% to $376.6 million in 2023, then dropped by 6.96% to $350.4 million in 2024, then increased by 14.53% to $401.3 million in 2025.
  • Its Total Liabilities stands at $401.3 million for Q4 2025, versus $365.5 million for Q3 2025 and $343.8 million for Q2 2025.